Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526140 | 0.81 | HPGD (0.57) | HPGDPOLBGAAPTPN22HSD17B10 | |
| SCHEMBL3816129 | 0.81 | HPGD (0.60) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL15413871 | 0.81 | HPGD (0.59) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL4372673 | 0.80 | HPGD (0.58) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL20554560 | 0.80 | HPGD (0.58) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL4252855 | 0.80 | HPGD (0.71) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL30618849 | 0.80 | HPGD (0.58) | HPGDPOLBGAATSHRMAPK1 | |
| SCHEMBL29235274 | 0.80 | HPGD (0.58) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL29956080 | 0.80 | HPGD (0.58) | HPGDPOLBGAAHSD17B10TSHR | |
| SCHEMBL4371294 | 0.79 | HPGD (0.56) | HPGDHSD17B10TSHRMAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221500-A | Preparation method of chloro aromatic compound | 大连理工大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-108368069-B | Oxazine compound, composition and cured product | DIC株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-108473642-B | Oxazine compound, composition and cured product | DIC株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-10913725-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| US-10399312-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-12-20 | — | — | US | disclosed |
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-11-22 | — | — | US | disclosed |
| EP-3401311-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3392281-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-108368069-A | Oxazine compound, composition and cured product | DIC株式会社 | 2018-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, PSMB5, CUL5 | HPGD 1322/4885POLB 2286/4885GAA 2221/4885 |
| US-10913725-B2 | Oxazine compound, composition and cured product | PSMB5, KDM5A, CUL5 | HPGD 1165/4885POLB 2399/4885GAA 2061/4885 |
| US-20180362479-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | PSMB5, KDM5A, CUL5 | HPGD 1165/4885POLB 2399/4885GAA 2061/4885 |
| US-10399312-B2 | Oxazine compound, composition and cured product | KDM5A, PSMB5, CUL5 | HPGD 1322/4885POLB 2286/4885GAA 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.